prognosis status
Otherobservatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
NCT Number: NCT06028217
The goal of this prospective and observatory study is to learn about the pathogen, clinical manifestations, prognosis, treatment and antibiotic resistance of bacteria in hospital-acquired pneumonia patients in China.
The main purposes of this study are:
1. clarify the regional differences and changes over time in the pathogen spectrum and antibiotic resistance rate among HAP patients in China; 2. build a continuously optimized nationwide HAP pathogen and antibiotic resistance surveillance network; 3. identify the molecular epidemiology of common pathogens
Trial opening soon.
Get Notified18 year–100 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
observatory; patients will be divided into survival group and mortality group according to their prognosis at day 28
Time frame: 28 days after enrollment
prognosis
Time frame: 0 day, 3 days, 7days, 14 days and 28 days after enrollment
symptoms, physical examinations, comorbidity, laboratory tests, imaging findings and treatment
Time frame: 0 day, 3 days, 7days, 14 days and 28 days after enrollment
molecular characteristics of responsible pathogen; antibiotic resistance of bacteria
Ruijin Hospital
Other
A Prospective Study on Pathogen Investigation, Risk Factors, and Prognostic Factors Analysis of Hospital Acquired Pneumonia (HAP)
Acronym: CHAPTER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04700202
Cross Infection, Disease Attributes
Dallas, Texas, United States
View Trial DetailsNCT04153682
Cross Infection, Disease Attributes
Créteil, France
View Trial DetailsNCT05483309
Cross Infection, Disease Attributes
Liverpool, United Kingdom
View Trial DetailsNCT05733104
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
Seoul, Gangnam-gu, South Korea
View Trial Details